Millennium Management’s Metagenomi Therapeutics MGX Stock Holding History

Millennium Management’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$228K	Sell	170,104 -65,081	-28%	-$101K	﹤0.01%	5123
2025 Q4	$381K	Sell	235,185 -75,507	-24%	-$163K	﹤0.01%	5116
2025 Q3	$736K	Sell	310,692 -72,341	-19%	-$147K	﹤0.01%	4840
2025 Q2	$567K	Buy	383,033 +197,925	+107%	+$310K	﹤0.01%	4820
2025 Q1	$252K	Buy	185,108 +170,699	+1,185%	+$407K	﹤0.01%	5188
2024 Q4	$52K	Sell	14,409 -403,469	-97%	-$973K	﹤0.01%	5586
2024 Q3	$907K	Buy	417,878 +104,716	+33%	+$363K	﹤0.01%	4359
2024 Q2	$1.23M	Sell	313,162 -434,386	-58%	-$2.98M	﹤0.01%	3958
2024 Q1	$7.57M	Buy	+747,548	New	+$8.59M	﹤0.01%	2450

Other funds holding MGX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management's MGX Position: Q1 2026 in Review

Millennium Management reduced its Metagenomi Therapeutics (MGX) stake by 28% in Q1 2026, selling an estimated $101K and leaving 170,104 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #5123.

Millennium Management first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $7.57M in Q1 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Millennium Management held 170,104 shares of Metagenomi Therapeutics worth $228K as of Q1 2026.
Millennium Management sold 65,081 Metagenomi Therapeutics shares in Q1 2026, an estimated $101K.
Metagenomi Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #5123 holding.
Millennium Management first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
Millennium Management's Metagenomi Therapeutics position peaked at $7.57M in Q1 2024.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.